Evidence-Informed Technical Advocacy for HPV Vaccine Introduction in Nigeria
Evidence-Informed Technical Advocacy for HPV Vaccine Introduction in Nigeria
Overview
Nigeria’s introduction of the HPV vaccine marked a major milestone in cervical cancer prevention, reaching millions of girls nationwide. The next challenge is sustaining high coverage over time while ensuring that immunization systems can continue to reach future generations of girls.
Through this Gates Foundation-funded initiative, MSH and local partners Women Advocates for Vaccine Access (WAVA) and the Solina Centre for International Development and Research (SCIDaR) are helping national and state leaders generate and apply evidence to strengthen HPV vaccine delivery. The project supports country-led decision-making, sustainable financing, stronger data systems, and practical implementation strategies that can improve long-term immunization performance.
Through a collaborative, government-led approach, MSH and partners:
- Generate and apply local evidence to improve vaccine delivery and program performance.
- Strengthen country and state leadership for immunization planning, coordination, and decision-making.
- Support sustainable financing and long-term ownership of HPV vaccination programs.
- Use data, modeling, and implementation research to identify and address barriers to coverage.
- Build partnerships among government, civil society, researchers, and communities to support equitable vaccine access.
Supporting Country-Led Immunization Systems
The lessons emerging from HPV vaccine introduction extend beyond a single vaccine. Research and policy analysis generated through this project are helping identify practical solutions to challenges related to financing, workforce capacity, data systems, community engagement, and service delivery.
By working alongside government institutions and local partners, MSH is helping build stronger immunization systems that can support the introduction, scale-up, and sustainability of vaccines over time—an approach that aligns with global efforts to reach more children and adolescents with life-saving immunization services.
New Research
June 2026 | Published in PLOS ONE, research conducted by MSH, WAVA, and SCIDaR identifies barriers to sustained HPV vaccine delivery across Kano, Kaduna, and Lagos States. The findings offer practical recommendations for strengthening financing, service delivery, data systems, workforce capacity, and community engagement—providing evidence that can inform future immunization efforts in Nigeria and beyond.
Nigeria Charts a Sustainable Path for HPV Vaccination: Evidence-Informed Advocacy to Strengthen Cervical Cancer Prevention
Factsheets and Policy and Programmatic Recommendations – Evidence-Informed Technical Advocacy for HPV Vaccine Introduction in Nigeria
Through the Evidence-Informed Technical Advocacy project, MSH and partners conducted research across Kano, Kaduna, and Lagos States to identify opportunities and challenges in sustaining HPV vaccine delivery.
John Adedoyin
Project Director
Project Contact
John Adedoyin brings over two decades of experience leading complex health programs across Nigeria. As Project Director, he drives implementation and partnerships to deliver results at scale and strengthen government-led systems.
Donors & Partners
Donors
Gates Foundation
Partners
Solina Centre for International Development and Research (SCIDaR)
Women Advocates for Vaccine Access (WAVA)